Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 367
interventional 349
Observational 17
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 218
Biological|Drug 27
Biological 24
Drug|placebo 18
Drug|Other 13
Drug|Radiation 11
Drug|Procedure 6
Biological|Drug|Other 4
Drug|Other|Procedure 3
Procedure 3
Biological|Drug|Procedure 2
Biological|Other 2
Diagnostic Test 2
Dietary Supplement|Drug 2
Behavioral|Drug 1
Behavioral|Other 1
Biological|Device 1
Biological|Device|Drug 1
Biological|Device|Drug|Procedure 1
Biological|Drug|Other|placebo 1
Biological|Drug|placebo 1
Biological|Drug|Radiation 1
Combination Product 1
Device 1
Device|Drug 1
Dietary Supplement 1
Drug|Other|Procedure|Radiation 1
Drug|Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 168
China 38
NA 9
France 6
United States|Canada 6
Canada 5
United Kingdom 5
Korea, Republic of 4
Belgium 3
Italy 3
Netherlands 3
United States|Australia 3
Australia 2
Germany 2
India 2
Israel 2
Russian Federation 2
Argentina|Chile|Czechia|France|Hungary|Italy|Mexico|Peru|Poland|Portugal|Slovakia|Slovenia|Spain 1
Australia|Austria|Belgium|Canada 1
Australia|Belgium|France|Italy|Netherlands|Spain 1
Australia|France|Spain|United Kingdom 1
Australia|Taiwan 1
Austria 1
Austria|Belgium|Denmark|Germany|Lithuania|Netherlands|Norway|Spain|Sweden 1
Belgium|France 1
Belgium|France|Italy|Norway|United Kingdom 1
Belgium|France|Japan|Netherlands 1
Belgium|Hungary|Spain 1
Brazil 1
Colombia 1
Czechia|United States|Belgium|France|Italy|Poland|Spain 1
Denmark|Norway 1
Egypt 1
France|Germany|Spain 1
France|United States|Argentina|Brazil|Canada|Czechia|India|Japan|Korea, Republic of|Mexico|Peru|Philippines|Poland|Portugal|Russian Federation|Saudi Arabia|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|United Kingdom 1
Germany|Sweden 1
Japan|Korea, Republic of 1
Mexico 1
Poland 1
Spain|United Kingdom 1
Sweden 1
Taiwan 1
United Kingdom|United States|Belgium|Canada|Czechia|France|Germany|Ireland|Italy|Korea, Republic of|Netherlands|Poland|Portugal|Spain|Taiwan 1
United States|Algeria|Argentina|Bosnia and Herzegovina|Brazil|China|Cuba|Egypt|Finland|France|Germany|Hungary|Italy|Kazakhstan|Korea, Republic of|Mexico|Montenegro|Morocco|Panama|Poland|Portugal|Russian Federation|Serbia|Singapore|South Africa|Spain|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Bosnia and Herzegovina|Brazil|Canada|Chile|Colombia|Costa Rica|Czechia|Estonia|Finland|France|Germany|Greece|Guatemala|Hong Kong|Hungary|Italy|Japan|Korea, Republic of|Latvia|Mexico|Norway|Panama|Poland|Romania|Russian Federation|Serbia|Singapore|Slovenia|Spain|Sweden|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|China|Colombia|Costa Rica|Czechia|Denmark|Finland|France|Greece|Hong Kong|Hungary|India|Ireland|Israel|Italy|Japan|Korea, Republic of|Mexico|New Zealand|Peru|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|South Africa|Spain|Switzerland|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|China|Czechia|Denmark|France|Germany|Hong Kong|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Mexico|Peru|Poland|Romania|Russian Federation|Singapore|Spain|Switzerland|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Canada|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Singapore|Spain|Taiwan|Thailand|United Kingdom 1
United States|Argentina|Belgium|Brazil|Korea, Republic of|Peru|Spain|United Kingdom 1
United States|Argentina|Brazil|Canada|China|Croatia|Czechia|France|Germany|Greece|India|Israel|Italy|Japan|Morocco|Romania|Russian Federation|Saudi Arabia|Slovakia|South Africa|Spain|Turkey|United Kingdom|Vietnam 1
United States|Australia|Austria|Belgium|Czechia|France|Germany|Hong Kong|Italy|Korea, Republic of|Spain|Taiwan|Turkey 1
United States|Australia|Austria|Belgium|Czechia|France|Germany|Italy|Japan|Netherlands|Singapore|Spain|Switzerland|Taiwan 1
United States|Australia|Austria|Brazil|Canada|France|Germany|Greece|Italy|Portugal|Spain|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Germany|Italy|Japan|Korea, Republic of|Poland|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Australia|Belgium|Czechia|France|Israel|Italy|Korea, Republic of|Latvia|Romania|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|Germany|Spain|Switzerland 1
United States|Australia|Brazil|Canada|Colombia|France|Germany|Ireland|Israel|Italy|Japan|Korea, Republic of|Poland|Portugal|Russian Federation|Singapore|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Australia|Brazil|Czech Republic|Germany|Ireland|Italy|Korea, Republic of|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|Chile|France|Germany|Israel|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|Puerto Rico|Spain|Switzerland 1
United States|Australia|Canada|Japan|Singapore|Spain|United Kingdom 1
United States|Australia|China|France|Germany|Hong Kong|Korea, Republic of|Poland|Russian Federation|Spain|Taiwan|Ukraine 1
United States|Australia|France|Germany|Israel|Korea, Republic of|Spain|United Kingdom 1
United States|Australia|France|Spain|United Kingdom 1
United States|Australia|Hong Kong|Israel|Italy|Japan|Netherlands|Singapore|Spain 1
United States|Belgium|Bulgaria|Croatia|North Macedonia|Serbia|Slovakia|Slovenia 1
United States|Belgium|Canada|France|Germany|Spain|United Kingdom 1
United States|Belgium|Canada|France|Israel|Italy|Singapore|Spain|Taiwan 1
United States|Belgium|Canada|Germany|Netherlands|Spain|Sweden|United Kingdom 1
United States|Belgium|Canada|Ireland|Italy|Spain|United Kingdom 1
United States|Belgium|Czechia|Italy|Netherlands|Spain 1
United States|Belgium|Finland|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Spain|Switzerland 1
United States|Belgium|France|Germany|Italy|Netherlands|Spain|United Kingdom 1
United States|Belgium|France|Germany|Spain|United Kingdom 1
United States|Belgium|Korea, Republic of|Netherlands|Poland 1
United States|Belgium|Spain 1
United States|Canada|Chile|Colombia|France|Germany|Hungary|Japan|Korea, Republic of|Poland|Spain|Taiwan|Ukraine|United Kingdom 1
United States|Canada|France|Germany|Hungary|Italy|Lebanon|Netherlands|Norway|Poland|Spain|Taiwan|Thailand|Turkey 1
United States|Canada|France|Israel|Italy|Japan|Singapore|Spain|Taiwan 1
United States|Canada|Italy|Spain|United Kingdom 1
United States|Canada|Korea, Republic of|Poland|Taiwan|United Kingdom 1
United States|Canada|Spain|United Kingdom 1
United States|China 1
United States|Denmark|France|Hong Kong|Spain|United Kingdom 1
United States|France|Argentina|Australia|Belgium|Brazil|Canada|Chile|China|Costa Rica|Czechia|Germany|Greece|Hungary|India|Italy|Japan|Korea, Republic of|Mexico|North Macedonia|Peru|Poland|Russian Federation|Singapore|Slovenia|South Africa|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|France|Israel|Spain|Taiwan 1
United States|France|Italy|Japan|Singapore|Spain 1
United States|France|Italy|Spain 1
United States|France|Spain 1
United States|Germany|Hong Kong|Japan 1
United States|Germany|Korea, Republic of|Netherlands|Spain|Taiwan|United Kingdom 1
United States|Germany|Korea, Republic of|Spain 1
United States|Israel 1
United States|Israel|Spain 1
United States|Italy|Taiwan|United Kingdom 1
United States|Japan 1
United States|Netherlands|Spain 1
United States|Norway|Spain|United Kingdom 1
United States|Portugal|Spain 1
United States|Spain|United Kingdom 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 134
2 21
3 8
4 19
5 13
6 11
7 7
8 6
9 9
10 14
11 8
12 8
13 5
14 8
15 1
16 1
17 4
18 3
20 6
21 5
22 1
23 1
24 1
25 4
26 1
27 4
28 1
29 2
30 1
32 1
35 1
36 1
37 1
38 2
39 1
40 1
42 1
43 1
47 2
48 1
50 1
53 1
54 1
56 2
65 1
66 1
71 1
77 1
79 1
84 1
104 1
120 1
140 2
141 1
158 2
164 1
172 1
178 1
193 1
230 1
239 1
243 1
248 1
266 1
346 1
428 1

Phase

Phase Study_Count
Phase 2 135
Phase 1 87
Phase 1/Phase 2 63
Phase 3 35
N/A 10
Early Phase 1 9
Phase 2/Phase 3 6
Phase 4 4

Number of Arms

Number_of_Arms Count_of_Studies
1 139
2 126
3 24
4 25
5 10
6 9
7 5
8 2
9 2
11 1
14 1
15 2
25 1
NA 2

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 5.00000 11.00 3.00000 11.0000 9.0000 64.00 200.0000 2.00
1st Qu. 15.00000 16.25 30.00000 55.5000 40.5000 223.25 377.5000 37.25
Median 24.00000 36.50 48.00000 120.0000 65.0000 385.00 634.0000 54.50
Mean 32.44444 122.00 97.87356 171.7302 102.4963 410.00 670.9429 102.75
3rd Qu. 39.00000 198.25 128.00000 170.5000 133.5000 489.75 814.0000 120.00
Max. 100.00000 500.00 770.00000 1732.0000 600.0000 932.00 2300.0000 300.00

Trial Group Type

group_type Group_Count
Experimental 683
Active Comparator 94
Placebo Comparator 16
Other 15
No Intervention 8
NA 2

Intervention Model

intervention_model Study_Count
Parallel Assignment 159
Single Group Assignment 154
Sequential Assignment 30
Factorial Assignment 3
Crossover Assignment 2
NA 1

Primary Purpose

primary_purpose Study_Count
Treatment 326
Basic Science 7
Other 6
Diagnostic 5
Screening 2
Health Services Research 1
Prevention 1
Supportive Care 1

Observational Studies

Studies by Country

Country Study_Count
United States 8
China 5
Brazil 1
France 1
Italy 1
Spain 1

Sites per Study

Site_count Study_Count
1 13
2 1
3 2
18 1

Enrollment Metrics

Measure Observational
Min 14.0000
1st Qu 31.0000
Median 68.0000
Mean 102.2941
3rd Qu 185.0000
Max 264.0000

Observation Model

observational_model Study_Count
Cohort 11
Case-Only 4
Case-Control 2

Time Perspective

time_perspective Study_Count
Prospective 14
Retrospective 2
Other 1

Registries

Studies by Country

Country Study_Count
United States 1

Sites per Study

Site_count Study_Count
13 1

Enrollment Metrics

Measure Registries
Min 1500
1st Qu 1500
Median 1500
Mean 1500
3rd Qu 1500
Max 1500

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
10 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03371017 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03371017 Recruiting Hoffmann-La Roche 2023-01-31
NCT03345485 Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03345485 Active, not recruiting Mundipharma-EDO GmbH 2021-12-31
NCT04441099 NBE-002 in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04441099 Recruiting NBE-Therapeutics AG 2023-07-31
NCT04434040 Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC https://ClinicalTrials.gov/show/NCT04434040 Recruiting Dana-Farber Cancer Institute 2022-04-30
NCT04429542 Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04429542 Recruiting Bicara Therapeutics 2022-12-31
NCT04177108 A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. https://ClinicalTrials.gov/show/NCT04177108 Recruiting Hoffmann-La Roche 2025-10-10
NCT03971409 Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03971409 Recruiting University of California, San Francisco 2021-07-30
NCT03829436 TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers https://ClinicalTrials.gov/show/NCT03829436 Recruiting Tempest Therapeutics 2022-02-18
NCT03818685 Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease https://ClinicalTrials.gov/show/NCT03818685 Recruiting Centre Leon Berard 2022-03-01
NCT03719326 A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies https://ClinicalTrials.gov/show/NCT03719326 Recruiting Arcus Biosciences, Inc. 2022-02-28
NCT03424005 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03424005 Recruiting Hoffmann-La Roche 2023-01-03
NCT03411161 S 81694 Plus Paclitaxel in Metastatic Breast Cancer https://ClinicalTrials.gov/show/NCT03411161 Completed Servier 2020-06-08
NCT03401385 First-in-human Study of DS-1062a for Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03401385 Recruiting Daiichi Sankyo, Inc. 2022-01-01
NCT03394027 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma https://ClinicalTrials.gov/show/NCT03394027 Recruiting National Institutes of Health Clinical Center (CC) 2022-08-01
NCT03310957 Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03310957 Recruiting Seattle Genetics, Inc. 2020-12-31
NCT03361800 Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC https://ClinicalTrials.gov/show/NCT03361800 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2022-01-15
NCT03337724 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03337724 Recruiting Hoffmann-La Roche 2021-12-22
NCT03333915 Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03333915 Active, not recruiting BeiGene 2020-02-02
NCT03330847 To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. https://ClinicalTrials.gov/show/NCT03330847 Recruiting AstraZeneca 2020-11-30
NCT03316586 A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03316586 Active, not recruiting Dana-Farber Cancer Institute 2021-05-31
NCT03304756 Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen https://ClinicalTrials.gov/show/NCT03304756 Completed Instituto Nacional de Cancer, Brazil 2012-04-15
NCT03301350 Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer https://ClinicalTrials.gov/show/NCT03301350 Active, not recruiting University of Wisconsin, Madison 2022-10-31
NCT03289962 A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors https://ClinicalTrials.gov/show/NCT03289962 Recruiting Genentech, Inc. 2020-09-11
NCT03281954 Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo https://ClinicalTrials.gov/show/NCT03281954 Recruiting NSABP Foundation Inc 2023-12-31
NCT03267316 A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors https://ClinicalTrials.gov/show/NCT03267316 Recruiting Cantargia AB 2020-07-31
NCT03256344 Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases https://ClinicalTrials.gov/show/NCT03256344 Recruiting Amgen 2020-07-13
NCT03254654 Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03254654 Recruiting Fudan University 2019-08-31
NCT03244358 Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03244358 Recruiting Sun Yat-sen University 2022-07-01
NCT03243331 An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03243331 Recruiting Indiana University 2021-01-01
NCT03207867 A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03207867 Recruiting Novartis 2021-10-05
NCT03206203 Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03206203 Recruiting Vanderbilt-Ingram Cancer Center 2021-01-31
NCT03199040 Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy https://ClinicalTrials.gov/show/NCT03199040 Recruiting Washington University School of Medicine 2021-09-30
NCT03197935 A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03197935 Active, not recruiting Hoffmann-La Roche 2020-04-02
NCT03197389 Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer. https://ClinicalTrials.gov/show/NCT03197389 Completed Universitaire Ziekenhuizen Leuven 2020-03-31
NCT03193853 TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03193853 Recruiting Baylor Research Institute 2021-06-09
NCT03184558 Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC https://ClinicalTrials.gov/show/NCT03184558 Completed BerGenBio ASA 2018-08-30
NCT03170960 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03170960 Recruiting Exelixis 2020-12-31
NCT03168880 A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03168880 Active, not recruiting Tata Memorial Hospital 2020-11-30
NCT03167619 Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) https://ClinicalTrials.gov/show/NCT03167619 Recruiting Duke University 2021-03-31
NCT03154749 TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03154749 Recruiting Guangdong Provincial People’s Hospital 2019-12-31
NCT03145961 A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT03145961 Active, not recruiting Institute of Cancer Research, United Kingdom 2021-06-01
NCT03122444 Imipramine on Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03122444 Recruiting The University of Texas Health Science Center at San Antonio 2020-12-31
NCT03121352 Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03121352 Completed Case Comprehensive Cancer Center 2020-02-06
NCT03109080 Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) https://ClinicalTrials.gov/show/NCT03109080 Active, not recruiting Institut Curie 2020-04-30
NCT03106415 Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03106415 Recruiting Mayo Clinic 2021-07-15
NCT03106077 Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03106077 Completed M.D. Anderson Cancer Center 2019-10-01
NCT03101280 A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03101280 Active, not recruiting Hoffmann-La Roche 2020-07-28
NCT03098550 A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread https://ClinicalTrials.gov/show/NCT03098550 Active, not recruiting Bristol-Myers Squibb 2020-08-30
NCT03094169 AVID100 in Advanced Epithelial Carcinomas https://ClinicalTrials.gov/show/NCT03094169 Recruiting Formation Biologics 2020-09-01
NCT03092934 A Study of AK-01 (LY3295668) in Solid Tumors https://ClinicalTrials.gov/show/NCT03092934 Active, not recruiting Eli Lilly and Company 2019-12-01
NCT03090165 Ribociclib and Bicalutamide in AR+ TNBC https://ClinicalTrials.gov/show/NCT03090165 Active, not recruiting Big Ten Cancer Research Consortium 2020-09-30
NCT03251378 A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer https://ClinicalTrials.gov/show/NCT03251378 Recruiting Hutchison Medipharma Limited 2021-06-15
NCT03057600 Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced TNBC https://ClinicalTrials.gov/show/NCT03057600 Completed Calithera Biosciences, Inc 2019-11-25
NCT03055312 Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03055312 Recruiting Sun Yat-sen University 2020-12-31
NCT03036488 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) https://ClinicalTrials.gov/show/NCT03036488 Active, not recruiting Merck Sharp & Dohme Corp. 2025-09-30
NCT03017573 Prospective Biobanking Study in Ovarian, Breast and Head and Neck Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) https://ClinicalTrials.gov/show/NCT03017573 Recruiting Institut Curie 2020-12-31
NCT03012230 Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03012230 Recruiting Mayo Clinic 2021-03-15
NCT03012100 Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03012100 Recruiting Academic and Community Cancer Research United 2021-07-31
NCT03004183 SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC https://ClinicalTrials.gov/show/NCT03004183 Recruiting The Methodist Hospital System 2022-05-31
NCT03002103 A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03002103 Recruiting SynCore Biotechnology Co., Ltd. 2023-03-31
NCT02996825 Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02996825 Recruiting City of Hope Medical Center 2023-02-22
NCT02993094 Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02993094 Recruiting Arbeitsgemeinschaft medikamentoese Tumortherapie 2020-09-30
NCT02984683 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02984683 Completed Sanofi 2018-08-13
NCT02981303 Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02981303 Active, not recruiting Biothera 2019-04-30
NCT02978716 Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) https://ClinicalTrials.gov/show/NCT02978716 Active, not recruiting G1 Therapeutics, Inc. 2018-07-30
NCT02978495 Neoadjuvant Carboplatin in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02978495 Recruiting Barretos Cancer Hospital 2019-12-31
NCT02977468 Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02977468 Recruiting Columbia University 2020-12-31
NCT02971761 Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02971761 Active, not recruiting City of Hope Medical Center 2020-11-03
NCT02950259 Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC) https://ClinicalTrials.gov/show/NCT02950259 Active, not recruiting Providence Health & Services 2018-04-26
NCT02938442 Vaccination of Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT02938442 Recruiting University of Arkansas 2021-11-30
NCT02936102 A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. https://ClinicalTrials.gov/show/NCT02936102 Active, not recruiting Novartis 2021-06-01
NCT02926690 Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02926690 Recruiting OncoTherapy Science, Inc. 2020-12-31
NCT02926196 Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab https://ClinicalTrials.gov/show/NCT02926196 Recruiting Istituto Oncologico Veneto IRCCS 2021-06-30
NCT02900664 A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) https://ClinicalTrials.gov/show/NCT02900664 Active, not recruiting Novartis 2020-08-21
NCT02898207 Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02898207 Active, not recruiting National Cancer Institute (NCI) 2020-12-01
NCT02897050 Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02897050 Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2020-12-31
NCT02890069 A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat https://ClinicalTrials.gov/show/NCT02890069 Recruiting Novartis 2021-05-28
NCT02883062 Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02883062 Active, not recruiting National Cancer Institute (NCI) 2020-07-01
NCT02834403 L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT02834403 Recruiting The Methodist Hospital System 2020-12-31
NCT02826434 Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02826434 Active, not recruiting Massachusetts General Hospital 2021-02-28
NCT02807844 Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT02807844 Active, not recruiting Novartis 2020-04-28
NCT02806258 Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone https://ClinicalTrials.gov/show/NCT02806258 Recruiting University Hospital, Grenoble 2021-03-31
NCT02789332 Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency https://ClinicalTrials.gov/show/NCT02789332 Completed German Breast Group 2019-02-28
NCT02788981 Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02788981 Recruiting University of Chicago 2022-02-28
NCT02755272 A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02755272 Recruiting Fox Chase Cancer Center 2021-10-31
NCT02750358 Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02750358 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT02744053 DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02744053 Recruiting M.D. Anderson Cancer Center 2020-11-30
NCT02734290 Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer https://ClinicalTrials.gov/show/NCT02734290 Active, not recruiting Providence Health & Services 2021-05-31
NCT02730130 Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT02730130 Active, not recruiting Memorial Sloan Kettering Cancer Center 2017-09-26
NCT02723877 PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) https://ClinicalTrials.gov/show/NCT02723877 Completed PIQUR Therapeutics AG 2018-10-03
NCT02719691 Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT02719691 Recruiting University of Colorado, Denver 2021-02-28
NCT02689427 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02689427 Recruiting M.D. Anderson Cancer Center 2020-09-30
NCT02688803 Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) https://ClinicalTrials.gov/show/NCT02688803 Completed Ottawa Hospital Research Institute 2017-10-31
NCT02670109 Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT02670109 Recruiting Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 2020-11-30
NCT02658214 Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02658214 Completed AstraZeneca 2019-11-14
NCT02657889 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer https://ClinicalTrials.gov/show/NCT02657889 Active, not recruiting Tesaro, Inc. 2018-05-31
NCT02644369 Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02644369 Active, not recruiting University Health Network, Toronto 2021-01-31
NCT02641847 TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature https://ClinicalTrials.gov/show/NCT02641847 Recruiting Fudan University 2021-06-30
NCT02637531 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 https://ClinicalTrials.gov/show/NCT02637531 Active, not recruiting Infinity Pharmaceuticals, Inc. 2020-12-31
NCT02624700 2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02624700 Active, not recruiting Virginia Commonwealth University 2019-07-10
NCT02622074 Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173) https://ClinicalTrials.gov/show/NCT02622074 Completed Merck Sharp & Dohme Corp. 2018-05-31
NCT02615457 Huaier Granule in Treating Women With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02615457 Recruiting Shandong University 2025-10-31
NCT02595138 Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT02595138 Active, not recruiting Chinese Academy of Medical Sciences 2018-10-31
NCT02593227 Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02593227 Active, not recruiting Marker Therapeutics, Inc. 2021-12-31
NCT02574455 ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02574455 Active, not recruiting Immunomedics, Inc. 2020-06-30
NCT04432857 AN0025 and Pembrolizumab Combination in Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04432857 Recruiting Adlai Nortye Biopharma Co., Ltd. 2022-12-31
NCT03125902 A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) https://ClinicalTrials.gov/show/NCT03125902 Active, not recruiting Hoffmann-La Roche 2019-11-15
NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer https://ClinicalTrials.gov/show/NCT02632448 Recruiting Esperas Pharma Inc. 2020-03-27
NCT02530489 Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02530489 Recruiting M.D. Anderson Cancer Center 2021-02-28
NCT03801369 Olaparib and Durvalumab in Treating Patients With Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03801369 Recruiting OHSU Knight Cancer Institute 2020-12-31
NCT02546934 ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) https://ClinicalTrials.gov/show/NCT02546934 Active, not recruiting Fudan University 2020-04-30
NCT02531932 Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02531932 Recruiting Icahn School of Medicine at Mount Sinai 2020-12-31
NCT02531425 Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC https://ClinicalTrials.gov/show/NCT02531425 Completed OncoSec Medical Incorporated 2018-07-31
NCT02527434 Study of Tremelimumab in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02527434 Active, not recruiting AstraZeneca 2018-02-17
NCT02521363 Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02521363 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-07-31
NCT02513472 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) https://ClinicalTrials.gov/show/NCT02513472 Completed Eisai Inc. 2019-07-31
NCT02489448 Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02489448 Recruiting Yale University 2020-10-31
NCT03387085 QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. https://ClinicalTrials.gov/show/NCT03387085 Active, not recruiting NantKwest, Inc. 2019-12-31
NCT02474173 Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02474173 Active, not recruiting National Cancer Institute (NCI) 2020-12-31
NCT02455141 Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02455141 Recruiting Shanghai Jiao Tong University School of Medicine 2021-06-30
NCT02447003 Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) https://ClinicalTrials.gov/show/NCT02447003 Completed Merck Sharp & Dohme Corp. 2020-01-31
NCT02441933 Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial) https://ClinicalTrials.gov/show/NCT02441933 Recruiting Yonsei University 2023-03-31
NCT02435680 Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) https://ClinicalTrials.gov/show/NCT02435680 Active, not recruiting Novartis 2020-07-20
NCT02427581 Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT02427581 Recruiting Washington University School of Medicine 2021-08-31
NCT02425891 A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) https://ClinicalTrials.gov/show/NCT02425891 Active, not recruiting Hoffmann-La Roche 2020-04-14
NCT02422498 Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy https://ClinicalTrials.gov/show/NCT02422498 Recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT02413320 Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02413320 Completed University of Kansas Medical Center 2019-02-01
NCT02411656 Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy https://ClinicalTrials.gov/show/NCT02411656 Recruiting M.D. Anderson Cancer Center 2020-06-01
NCT02402764 Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) https://ClinicalTrials.gov/show/NCT02402764 Completed H. Lee Moffitt Cancer Center and Research Institute 2016-03-10
NCT02401347 Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumors https://ClinicalTrials.gov/show/NCT02401347 Recruiting Stanford University 2021-08-31
NCT02375958 PCA062 in pCAD-positive Tumors. https://ClinicalTrials.gov/show/NCT02375958 Completed Novartis 2018-07-17
NCT02370238 A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02370238 Active, not recruiting Dompé Farmaceutici S.p.A 2018-12-31
NCT02352025 S-equol in Women With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02352025 Active, not recruiting The University of Texas Health Science Center at San Antonio 2019-04-10
NCT02341911 Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC) https://ClinicalTrials.gov/show/NCT02341911 Recruiting Fudan University 2019-12-31
NCT02322814 A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread https://ClinicalTrials.gov/show/NCT02322814 Active, not recruiting Hoffmann-La Roche 2018-08-10
NCT02316457 RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID https://ClinicalTrials.gov/show/NCT02316457 Active, not recruiting Biontech SE 2020-06-30
NCT02315196 Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer https://ClinicalTrials.gov/show/NCT02315196 Recruiting Rutgers, The State University of New Jersey 2022-07-31
NCT02307240 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors https://ClinicalTrials.gov/show/NCT02307240 Completed Curis, Inc. 2019-05-31
NCT02301988 A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02301988 Completed Genentech, Inc. 2017-08-02
NCT02266420 Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm https://ClinicalTrials.gov/show/NCT02266420 Active, not recruiting Institut Claudius Regaud 2023-06-30
NCT02259114 A Dose-Finding Study of MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) https://ClinicalTrials.gov/show/NCT02259114 Completed Oncoethix GmbH 2017-03-03
NCT02225470 Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes https://ClinicalTrials.gov/show/NCT02225470 Completed Eisai Inc. 2017-09-29
NCT02203513 A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer https://ClinicalTrials.gov/show/NCT02203513 Active, not recruiting National Institutes of Health Clinical Center (CC) 2021-06-01
NCT02183805 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT02183805 Recruiting Sun Yat-sen University 2022-12-31
NCT02178722 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers https://ClinicalTrials.gov/show/NCT02178722 Active, not recruiting Incyte Corporation 2018-11-26
NCT02158507 Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02158507 Active, not recruiting University of Alabama at Birmingham 2020-12-31
NCT02130700 Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer https://ClinicalTrials.gov/show/NCT02130700 Completed Innocrin Pharmaceutical 2017-09-30
NCT02124902 Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity https://ClinicalTrials.gov/show/NCT02124902 Recruiting Washington University School of Medicine 2021-03-31
NCT02101385 Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02101385 Active, not recruiting Hoosier Cancer Research Network 2021-06-30
NCT02071862 Study of the Glutaminase Inhibitor CB-839 in Solid Tumors https://ClinicalTrials.gov/show/NCT02071862 Completed Calithera Biosciences, Inc 2019-03-31
NCT01307891 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01307891 Completed University of Alabama at Birmingham 2016-06-30
NCT01306032 Phase II ABT-888 With Cyclophosphamide https://ClinicalTrials.gov/show/NCT01306032 Completed National Institutes of Health Clinical Center (CC) 2014-12-31
NCT01287624 Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC) https://ClinicalTrials.gov/show/NCT01287624 Completed Fudan University 2014-03-31
NCT02032277 A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02032277 Active, not recruiting AbbVie 2016-03-18
NCT03358017 Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03358017 Recruiting Mario Negri Institute for Pharmacological Research 2020-07-25
NCT03356860 Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. https://ClinicalTrials.gov/show/NCT03356860 Recruiting Grand Hôpital de Charleroi 2021-04-30
NCT02768701 Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02768701 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2023-03-15
NCT02348320 Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT02348320 Completed Washington University School of Medicine 2020-03-12
NCT02014337 Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors https://ClinicalTrials.gov/show/NCT02014337 Completed Corcept Therapeutics 2017-12-31
NCT02001519 Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT02001519 Completed Asan Medical Center 2014-02-28
NCT01997333 Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01997333 Completed Celldex Therapeutics 2017-11-30
NCT01986426 LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab https://ClinicalTrials.gov/show/NCT01986426 Completed Lytix Biopharma AS 2018-04-30
NCT01982448 Cisplatin vs Paclitaxel for Triple Neg https://ClinicalTrials.gov/show/NCT01982448 Active, not recruiting Dana-Farber Cancer Institute 2019-04-30
NCT01969032 Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01969032 Completed Russian Academy of Medical Sciences 2014-05-31
NCT01964924 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01964924 Completed National Cancer Institute (NCI) 2017-01-20
NCT01931163 NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer https://ClinicalTrials.gov/show/NCT01931163 Completed The Methodist Hospital System 2019-01-31
NCT01920061 A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) https://ClinicalTrials.gov/show/NCT01920061 Recruiting Pfizer 2020-01-10
NCT01898117 Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01898117 Recruiting The Netherlands Cancer Institute 2020-12-31
NCT01889238 Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01889238 Active, not recruiting Pfizer 2015-03-01
NCT01884285 AZD8186 First Time In Patient Ascending Dose Study https://ClinicalTrials.gov/show/NCT01884285 Completed AstraZeneca 2019-03-31
NCT01881230 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) https://ClinicalTrials.gov/show/NCT01881230 Completed Celgene 2016-10-28
NCT01837602 cMet CAR RNA T Cells Targeting Breast Cancer https://ClinicalTrials.gov/show/NCT01837602 Completed University of Pennsylvania 2018-08-13
NCT01818063 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer https://ClinicalTrials.gov/show/NCT01818063 Completed Thomas Jefferson University 2015-03-01
NCT01815242 Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01815242 Active, not recruiting West German Study Group 2015-03-31
NCT01805076 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer https://ClinicalTrials.gov/show/NCT01805076 Active, not recruiting Alliance for Clinical Trials in Oncology 2025-02-28
NCT01770353 MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment https://ClinicalTrials.gov/show/NCT01770353 Completed Ipsen 2018-10-02
NCT01677455 An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer https://ClinicalTrials.gov/show/NCT01677455 Completed Synta Pharmaceuticals Corp. 2015-04-30
NCT01676753 Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer https://ClinicalTrials.gov/show/NCT01676753 Active, not recruiting University of California, San Francisco 2020-06-01
NCT01674842 Cisplatin + RT for Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01674842 Active, not recruiting Dana-Farber Cancer Institute 2018-08-31
NCT01672671 BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy https://ClinicalTrials.gov/show/NCT01672671 Completed Russian Academy of Medical Sciences 2015-06-30
NCT01650506 Study of Erlotinib and Metformin in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01650506 Completed Columbia University 2016-06-30
NCT01639248 Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC https://ClinicalTrials.gov/show/NCT01639248 Completed CASI Pharmaceuticals, Inc. 2017-06-30
NCT01631552 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers https://ClinicalTrials.gov/show/NCT01631552 Active, not recruiting Immunomedics, Inc. 2020-06-30
NCT01624441 Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01624441 Completed National Cancer Institute (NCI) 2013-09-10
NCT01623349 Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer https://ClinicalTrials.gov/show/NCT01623349 Active, not recruiting Dana-Farber Cancer Institute 2019-05-31
NCT01618136 An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT01618136 Completed Eisai Inc. 2015-07-31
NCT01617668 A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01617668 Completed Novartis 2014-09-30
NCT01525966 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01525966 Active, not recruiting City of Hope Medical Center 2023-02-28
NCT01520389 Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment https://ClinicalTrials.gov/show/NCT01520389 Completed Merrimack Pharmaceuticals 2015-12-31
NCT01467310 Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 https://ClinicalTrials.gov/show/NCT01467310 Completed UNC Lineberger Comprehensive Cancer Center 2016-04-30
NCT01451632 A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers https://ClinicalTrials.gov/show/NCT01451632 Completed Merrimack Pharmaceuticals 2013-11-30
NCT01421472 A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer https://ClinicalTrials.gov/show/NCT01421472 Completed Merrimack Pharmaceuticals 2013-12-31
NCT01391143 Safety Study of MGA271 in Refractory Cancer https://ClinicalTrials.gov/show/NCT01391143 Completed MacroGenics 2019-04-18
NCT01372579 Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT01372579 Active, not recruiting Northwestern University 2020-06-30
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands https://ClinicalTrials.gov/show/NCT01351103 Recruiting Novartis 2022-03-25
NCT04437160 Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT04437160 Recruiting Chinese Academy of Medical Sciences 2026-01-31
NCT04418154 Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT04418154 Recruiting Fudan University 2021-06-15
NCT03599453 Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03599453 Recruiting Roswell Park Cancer Institute 2021-06-06
NCT04403529 Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT04403529 Recruiting Fudan University 2024-05-31
NCT04395989 An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. https://ClinicalTrials.gov/show/NCT04395989 Recruiting Fudan University 2022-11-15
NCT04344795 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors https://ClinicalTrials.gov/show/NCT04344795 Recruiting Tempest Therapeutics 2021-08-31
NCT04335669 NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC https://ClinicalTrials.gov/show/NCT04335669 Recruiting Lund University Hospital 2023-06-25
NCT04332653 NT-I7 (Hyleukin-7) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04332653 Recruiting NeoImmuneTech 2022-06-30
NCT04301011 Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors https://ClinicalTrials.gov/show/NCT04301011 Recruiting Turnstone Biologics, Corp. 2022-08-20
NCT04297267 A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT04297267 Recruiting Fudan University 2022-12-31
NCT04296175 Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) https://ClinicalTrials.gov/show/NCT04296175 Recruiting Fudan University 2024-06-30
NCT04251533 Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss Without PIK3CA Mutation https://ClinicalTrials.gov/show/NCT04251533 Recruiting Novartis 2023-06-19
NCT04249167 Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT04249167 Recruiting Mayo Clinic 2020-12-31
NCT04248998 Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT04248998 Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2022-12-31
NCT04234113 Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT04234113 Recruiting Sotio a.s. 2022-03-31
NCT04224922 Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT04224922 Completed AZ-VUB 2016-07-31
NCT04216472 Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations https://ClinicalTrials.gov/show/NCT04216472 Recruiting M.D. Anderson Cancer Center 2021-12-31
NCT04191135 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) https://ClinicalTrials.gov/show/NCT04191135 Recruiting Merck Sharp & Dohme Corp. 2026-01-26
NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression https://ClinicalTrials.gov/show/NCT04180371 Recruiting Bicycle Tx Limited 2022-12-31
NCT04176848 CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT04176848 Recruiting Canadian Cancer Trials Group 2022-05-30
NCT04159818 Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients https://ClinicalTrials.gov/show/NCT04159818 Recruiting The Netherlands Cancer Institute 2022-12-15
NCT04159142 Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT04159142 Recruiting Hebei Medical University Fourth Hospital 2022-06-20
NCT04158336 A Study of ZN-c3 in Participants With Solid Tumors https://ClinicalTrials.gov/show/NCT04158336 Recruiting K-Group Beta 2023-05-31
NCT04157517 A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study https://ClinicalTrials.gov/show/NCT04157517 Recruiting Takeda 2023-02-15
NCT04152499 Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies https://ClinicalTrials.gov/show/NCT04152499 Recruiting Klus Pharma Inc. 2021-12-31
NCT04148911 A Study of Atezolizumab Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT04148911 Recruiting Hoffmann-La Roche 2024-05-21
NCT04142931 Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Removal of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT04142931 Recruiting Sheba Medical Center 2021-12-30
NCT04138719 Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer https://ClinicalTrials.gov/show/NCT04138719 Recruiting Hebei Medical University Fourth Hospital 2020-10-20
NCT04134884 Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer https://ClinicalTrials.gov/show/NCT04134884 Recruiting Indiana University 2020-12-31
NCT04129996 A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) https://ClinicalTrials.gov/show/NCT04129996 Recruiting Fudan University 2021-01-01
NCT04115306 Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT04115306 Recruiting Phoenix Molecular Designs 2022-09-30
NCT04111510 Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT04111510 Recruiting Yale University 2022-01-31
NCT04105582 Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells https://ClinicalTrials.gov/show/NCT04105582 Recruiting Universidad Nacional de Colombia 2020-08-01
NCT04085276 Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment https://ClinicalTrials.gov/show/NCT04085276 Recruiting Shanghai Junshi Bioscience Co., Ltd. 2022-02-28
NCT04083963 Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT04083963 Recruiting University of Illinois at Chicago 2022-02-05
NCT04081389 Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT04081389 Recruiting Roswell Park Cancer Institute 2022-07-30
NCT04067102 Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC https://ClinicalTrials.gov/show/NCT04067102 Recruiting Hebei Medical University Fourth Hospital 2021-05-31
NCT04060342 GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma https://ClinicalTrials.gov/show/NCT04060342 Recruiting Gossamer Bio Inc. 2023-03-31
NCT04032080 Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib https://ClinicalTrials.gov/show/NCT04032080 Recruiting Baylor Research Institute 2021-06-30
NCT04031703 Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN) https://ClinicalTrials.gov/show/NCT04031703 Completed Fudan University 2016-04-20
NCT04030507 Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer https://ClinicalTrials.gov/show/NCT04030507 Recruiting Dana-Farber Cancer Institute 2022-07-01
NCT04025216 A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers https://ClinicalTrials.gov/show/NCT04025216 Recruiting Tmunity Therapeutics 2022-12-31
NCT04024800 Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT04024800 Recruiting Antigen Express, Inc 2023-06-30
NCT04004910 Immunopheresis Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Advanced Triple Negative Breast Cancer (TNBC) https://ClinicalTrials.gov/show/NCT04004910 Recruiting Immunicom Inc 2020-12-31
NCT03997123 Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC https://ClinicalTrials.gov/show/NCT03997123 Recruiting AstraZeneca 2022-06-10
NCT03992131 A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) https://ClinicalTrials.gov/show/NCT03992131 Recruiting Clovis Oncology, Inc. 2023-10-31
NCT03982173 Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03982173 Active, not recruiting Gustave Roussy, Cancer Campus, Grand Paris 2021-04-30
NCT03961698 Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) https://ClinicalTrials.gov/show/NCT03961698 Recruiting Infinity Pharmaceuticals, Inc. 2022-08-01
NCT03945721 A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT03945721 Recruiting Massachusetts General Hospital 2021-05-31
NCT03945604 A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC https://ClinicalTrials.gov/show/NCT03945604 Recruiting Jiangsu HengRui Medicine Co., Ltd. 2021-04-20
NCT03917381 GEN1046 Safety Trial in Patients With Malignant Solid Tumors https://ClinicalTrials.gov/show/NCT03917381 Recruiting Genmab 2021-10-31
NCT03901469 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03901469 Recruiting Zenith Epigenetics 2020-09-30
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03893955 Recruiting AbbVie 2023-05-11
NCT03891953 Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. https://ClinicalTrials.gov/show/NCT03891953 Recruiting Novartis 2022-11-28
NCT03881605 MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC https://ClinicalTrials.gov/show/NCT03881605 Recruiting Sunnybrook Health Sciences Centre 2021-06-30
NCT03876886 The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency https://ClinicalTrials.gov/show/NCT03876886 Recruiting Chinese Academy of Medical Sciences 2024-02-29
NCT03875313 Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT03875313 Recruiting Calithera Biosciences, Inc 2020-12-31
NCT03872791 A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03872791 Recruiting Jiangsu Alphamab Biopharmaceuticals Co., Ltd 2020-09-15
NCT03872388 Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT03872388 Recruiting M.D. Anderson Cancer Center 2021-12-31
NCT03861403 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03861403 Active, not recruiting Leap Therapeutics, Inc. 2021-06-30
NCT03855358 A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC) https://ClinicalTrials.gov/show/NCT03855358 Recruiting Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2020-06-30
NCT03853707 Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03853707 Recruiting City of Hope Medical Center 2022-06-21
NCT03838367 Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC https://ClinicalTrials.gov/show/NCT03838367 Recruiting CytoDyn, Inc. 2020-03-31
NCT03829501 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer https://ClinicalTrials.gov/show/NCT03829501 Recruiting Kymab Limited 2023-05-31
NCT03812393 Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast https://ClinicalTrials.gov/show/NCT03812393 Recruiting West Cancer Center 2020-10-15
NCT03808662 Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung https://ClinicalTrials.gov/show/NCT03808662 Recruiting Memorial Sloan Kettering Cancer Center 2022-01-31
NCT03808337 Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease https://ClinicalTrials.gov/show/NCT03808337 Recruiting Memorial Sloan Kettering Cancer Center 2022-01-31
NCT03805399 FUSCC Refractory TNBC Umbrella (FUTURE) https://ClinicalTrials.gov/show/NCT03805399 Recruiting Fudan University 2022-01-01
NCT03800836 A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03800836 Recruiting Hoffmann-La Roche 2022-10-29
NCT03799679 Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03799679 Recruiting Fudan University 2019-11-30
NCT03775928 Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03775928 Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2020-12-01
NCT03775850 A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors https://ClinicalTrials.gov/show/NCT03775850 Recruiting Evelo Biosciences, Inc. 2020-12-19
NCT03761914 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers https://ClinicalTrials.gov/show/NCT03761914 Recruiting Sellas Life Sciences Group 2020-12-31
NCT03756298 Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03756298 Recruiting National Cancer Center, Korea 2024-01-31
NCT03752723 Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) https://ClinicalTrials.gov/show/NCT03752723 Recruiting Genexine, Inc. 2021-07-31
NCT03750240 Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy https://ClinicalTrials.gov/show/NCT03750240 Recruiting NYU Langone Health 2020-08-31
NCT03742349 Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). https://ClinicalTrials.gov/show/NCT03742349 Recruiting Novartis 2022-01-17
NCT03742102 A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03742102 Recruiting AstraZeneca 2020-12-30
NCT03740893 PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03740893 Recruiting Institute of Cancer Research, United Kingdom 2023-03-31
NCT03739931 Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT03739931 Recruiting ModernaTX, Inc. 2020-06-30
NCT03735082 Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03735082 Recruiting Chinese Academy of Medical Sciences 2020-06-01
NCT03720431 TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03720431 Active, not recruiting PharmAbcine 2020-04-30
NCT03709446 Leflunomide in Previously Treated Metastatic Triple Negative Cancers https://ClinicalTrials.gov/show/NCT03709446 Recruiting Icahn School of Medicine at Mount Sinai 2021-10-20
NCT03674827 A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC https://ClinicalTrials.gov/show/NCT03674827 Recruiting Pfizer 2023-12-25
NCT03674242 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 1st Line Treatment of TNBC (TRYbeCA-2) https://ClinicalTrials.gov/show/NCT03674242 Recruiting ERYtech Pharma 2020-12-31
NCT03671044 A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT03671044 Recruiting Jina Pharmaceuticals Inc. 2022-03-31
NCT03667716 COM701 in Subjects With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03667716 Recruiting Compugen Ltd 2021-06-30
NCT03665285 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03665285 Recruiting NextCure, Inc. 2021-05-01
NCT03654547 Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03654547 Recruiting TransThera Biosciences Co., Ltd 2020-03-31
NCT03652077 A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies https://ClinicalTrials.gov/show/NCT03652077 Recruiting Incyte Corporation 2021-01-31
NCT03650738 This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment https://ClinicalTrials.gov/show/NCT03650738 Recruiting The First Affiliated Hospital with Nanjing Medical University 2019-12-30
NCT03639948 Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03639948 Recruiting University of Kansas Medical Center 2021-11-30
NCT03634150 Safety and Efficacy of IV Nerofeâ„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03634150 Recruiting Immune System Key Ltd 2020-06-30
NCT03616886 Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC https://ClinicalTrials.gov/show/NCT03616886 Recruiting Jules Bordet Institute 2022-09-30
NCT03609671 Emotions Immunology and Breast Cancer https://ClinicalTrials.gov/show/NCT03609671 Completed The Methodist Hospital System 2019-03-18
NCT03579472 M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03579472 Recruiting M.D. Anderson Cancer Center 2021-10-31
NCT03577743 Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03577743 Recruiting Assiut University 2020-05-31
NCT03576131 GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors https://ClinicalTrials.gov/show/NCT03576131 Recruiting Genmab 2021-12-31
NCT03567720 Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC https://ClinicalTrials.gov/show/NCT03567720 Active, not recruiting OncoSec Medical Incorporated 2023-07-31
NCT03562637 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy. https://ClinicalTrials.gov/show/NCT03562637 Recruiting OBI Pharma, Inc 2025-11-30
NCT03549000 A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. https://ClinicalTrials.gov/show/NCT03549000 Recruiting Novartis 2022-01-24
NCT03542175 A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy https://ClinicalTrials.gov/show/NCT03542175 Recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT03538028 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies https://ClinicalTrials.gov/show/NCT03538028 Recruiting Incyte Corporation 2020-09-24
NCT03519178 A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy https://ClinicalTrials.gov/show/NCT03519178 Recruiting Pfizer 2023-03-19
NCT03504488 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT03504488 Recruiting BioAtla, LLC 2020-05-13
NCT03499899 A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03499899 Active, not recruiting Novartis 2020-02-27
NCT03498716 A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03498716 Recruiting Hoffmann-La Roche 2022-01-15
NCT03487666 OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease https://ClinicalTrials.gov/show/NCT03487666 Recruiting Georgetown University 2021-12-31
NCT03483012 Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis https://ClinicalTrials.gov/show/NCT03483012 Recruiting Dana-Farber Cancer Institute 2021-09-30
NCT03464942 Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03464942 Recruiting Peter MacCallum Cancer Centre, Australia 2021-10-31
NCT03457779 Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03457779 Active, not recruiting Baylor Research Institute 2020-04-08
NCT03454451 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers https://ClinicalTrials.gov/show/NCT03454451 Recruiting Corvus Pharmaceuticals, Inc. 2022-03-31
NCT03435640 A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies https://ClinicalTrials.gov/show/NCT03435640 Recruiting Nektar Therapeutics 2021-09-30
NCT03414684 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03414684 Recruiting Dana-Farber Cancer Institute 2021-06-30
NCT01238952 Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01238952 Completed Nippon Kayaku Co., Ltd. 2010-11-30
NCT01216111 Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN) https://ClinicalTrials.gov/show/NCT01216111 Completed Fudan University 2016-04-20
NCT01204125 Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT01204125 Completed Sanofi 2012-10-31
NCT01186991 Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01186991 Completed Genentech, Inc. 2016-03-31
NCT01176669 Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT01176669 Completed Fudan University 2014-06-30
NCT01173497 A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis https://ClinicalTrials.gov/show/NCT01173497 Completed Sanofi 2012-10-31
NCT01150513 Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT01150513 Completed Chinese Academy of Medical Sciences 2016-01-31
NCT01116648 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01116648 Active, not recruiting National Cancer Institute (NCI) 2018-10-31
NCT01111825 Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01111825 Completed Puma Biotechnology, Inc. 2016-07-31
NCT01104259 Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer https://ClinicalTrials.gov/show/NCT01104259 Completed University of Washington 2015-02-28
NCT01097642 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT01097642 Completed The Methodist Hospital System 2019-12-31
NCT01094184 A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01094184 Completed Hoffmann-La Roche 2015-12-31
NCT01091454 Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer https://ClinicalTrials.gov/show/NCT01091454 Completed Alliance for Clinical Trials in Oncology 2012-06-30
NCT01074970 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations https://ClinicalTrials.gov/show/NCT01074970 Completed Hoosier Cancer Research Network 2018-12-15
NCT01045304 Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01045304 Completed Sanofi 2011-03-31
NCT00998036 Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors https://ClinicalTrials.gov/show/NCT00998036 Completed Columbia University 2012-06-30
NCT00986609 MUC1 Vaccine for Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT00986609 Completed Case Comprehensive Cancer Center 2013-08-29
NCT00951054 A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT00951054 Completed Nippon Kayaku Co., Ltd. 2014-12-31
NCT00887575 Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer https://ClinicalTrials.gov/show/NCT00887575 Completed SCRI Development Innovations, LLC 2013-07-31
NCT03911973 Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers https://ClinicalTrials.gov/show/NCT03911973 Recruiting Big Ten Cancer Research Consortium 2021-05-31
NCT03621982 Study of ADCT-301 in Patients With Selected Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03621982 Recruiting ADC Therapeutics S.A. 2021-03-31
NCT03362060 PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03362060 Recruiting Massachusetts General Hospital 2021-12-31
NCT00813956 A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT00813956 Completed Sanofi 2012-10-31
NCT03907800 Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer https://ClinicalTrials.gov/show/NCT03907800 Recruiting Ruijin Hospital 2022-10-31
NCT03849469 A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03849469 Recruiting Xencor, Inc. 2026-09-30
NCT03544125 Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03544125 Active, not recruiting OHSU Knight Cancer Institute 2018-08-07
NCT03164993 Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03164993 Recruiting Oslo University Hospital 2021-08-01
NCT03075462 A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients https://ClinicalTrials.gov/show/NCT03075462 Active, not recruiting Jiangsu HengRui Medicine Co., Ltd. 2019-12-31
NCT02819518 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) https://ClinicalTrials.gov/show/NCT02819518 Active, not recruiting Merck Sharp & Dohme Corp. 2019-12-30
NCT02583542 A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers https://ClinicalTrials.gov/show/NCT02583542 Active, not recruiting Queen Mary University of London 2020-03-31
NCT02580448 CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) https://ClinicalTrials.gov/show/NCT02580448 Completed Innocrin Pharmaceutical 2019-01-31
NCT02779855 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02779855 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2021-08-31
NCT02499367 Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients https://ClinicalTrials.gov/show/NCT02499367 Active, not recruiting The Netherlands Cancer Institute 2020-08-31
NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) https://ClinicalTrials.gov/show/NCT03797326 Active, not recruiting Merck Sharp & Dohme Corp. 2024-02-24
NCT02404441 Phase I/II Study of PDR001 in Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT02404441 Active, not recruiting Novartis 2020-07-01
NCT02555657 Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) https://ClinicalTrials.gov/show/NCT02555657 Active, not recruiting Merck Sharp & Dohme Corp. 2019-04-11
NCT00733408 Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer https://ClinicalTrials.gov/show/NCT00733408 Completed University of Washington 2017-07-05
NCT00707707 Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT00707707 Completed AstraZeneca 2009-11-09
NCT00371254 A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-negative’ Breast Cancer https://ClinicalTrials.gov/show/NCT00371254 Completed Bristol-Myers Squibb 2008-09-30
NCT00031681 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) https://ClinicalTrials.gov/show/NCT00031681 Completed National Cancer Institute (NCI) 2011-01-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03165487 Comparison of the Breast Tumor Microenvironment https://ClinicalTrials.gov/show/NCT03165487 Recruiting Columbia University 2020-06-30
NCT02247037 Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT02247037 Completed Icahn School of Medicine at Mount Sinai 2019-01-22
NCT01957514 Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy https://ClinicalTrials.gov/show/NCT01957514 Active, not recruiting University of Washington 2020-12-31
NCT01560663 Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT01560663 Recruiting Hospital General Universitario Gregorio Marañon 2019-12-31
NCT01395056 Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT01395056 Completed Beijing Cancer Hospital 2014-12-31
NCT04362462 Molecular Profiling After Neoadjuvant Chemotherapy for Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT04362462 Recruiting Texas Tech University Health Sciences Center, El Paso 2022-12-31
NCT04250818 Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile https://ClinicalTrials.gov/show/NCT04250818 Recruiting Texas Tech University Health Sciences Center, El Paso 2022-07-31
NCT04145947 Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT04145947 Recruiting Peking Union Medical College Hospital 2020-03-31
NCT04068623 Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT04068623 Recruiting Centre Jean Perrin 2022-10-31
NCT04059003 CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT04059003 Recruiting Shengjing Hospital 2023-08-31
NCT04045522 Study on Bisphosphonates Targeting Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT04045522 Recruiting Shengjing Hospital 2021-08-31
NCT03981705 Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer https://ClinicalTrials.gov/show/NCT03981705 Recruiting Masonic Cancer Center, University of Minnesota 2025-01-31
NCT03920488 Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer https://ClinicalTrials.gov/show/NCT03920488 Recruiting European Institute of Oncology 2020-12-31
NCT03586297 Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer https://ClinicalTrials.gov/show/NCT03586297 Recruiting Hackensack Meridian Health 2021-05-01
NCT03539965 Triple-negative Breast Cancer: a New Perspective on Biomarkers https://ClinicalTrials.gov/show/NCT03539965 Completed Instituto Nacional de Cancer, Brazil 2014-12-31
NCT01232062 Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients https://ClinicalTrials.gov/show/NCT01232062 Completed Beijing Cancer Hospital 2011-05-31
NCT01111175 Triple Negative Breast Cancer Biomarker Study https://ClinicalTrials.gov/show/NCT01111175 Completed US Oncology Research 2013-06-30

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02302742 Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry https://ClinicalTrials.gov/show/NCT02302742 Recruiting University of Kansas Medical Center 2024-03-31